Logo

Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia

Share this

Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia

Shots:

  • The BTD is based on P-II 1346.9 clinical trial- which demonstrated that BI 425809 improved cognition in adult patients with schizophrenia
  • Moreover- the company has initiated the P-III CONNEX program assessing the safety and efficacy of BI 425809 vs PBO for improving cognition in adults with schizophrenia over a 26wks. treatment period
  • Additionally- Boehringer Ingelheim will also use VeraSci's VRFCAT which is an assessment that improves clinical trials by detecting functional improvements in patients' everyday lives. BI 425809 is a novel glycine transporter-1 (GlyT1) inhibitor

  Ref: PRNewswire | Image: Pharmaceutical Technology

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions